The application of nanoparticles as advanced drug delivery systems in Attenuating COPD
Victoria Jessamine,
Samir Mehndiratta,
Gabriele De Rubis,
Keshav Raj Paudel,
Saritha Shetty,
Divya Suares,
Dinesh Kumar Chellappan,
Brian G. Oliver,
Phillip M. Hansbro,
Kamal Dua
Affiliations
Victoria Jessamine
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia
Samir Mehndiratta
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia; Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia
Gabriele De Rubis
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia; Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia
Keshav Raj Paudel
Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute and University of technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, 2007, Australia
Saritha Shetty
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's, NMIMS Deemed to Be University, Mumbai, 400056, Maharashtra, India
Divya Suares
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's, NMIMS Deemed to Be University, Mumbai, 400056, Maharashtra, India
Dinesh Kumar Chellappan
Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 578000, Malaysia
Brian G. Oliver
School of Life Sciences, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia
Phillip M. Hansbro
Centre for Inflammation, Centenary Institute and University of technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, 2007, Australia
Kamal Dua
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia; Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Corresponding author. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia.
Chronic Obstructive Pulmonary Disease (COPD) is a dilapidating condition which is characterized by inflammation, an excess in free radical generation and airway obstruction. Currently, the drugs commercially available for the management of COPD pose several limitations such as systemic adverse effects, including bone density loss and an increased risk of developing pneumonia. Moreover, another limitation includes the need for regular and frequent dosing regimens; which can affect the adherence to the therapy. Furthermore, these current treatments provide symptomatic relief; however, they cannot stop the progression of COPD. Comparatively, nanoparticles (NPs) provide great therapeutic potential to treat COPD due to their high specificity, biocompatibility, and higher bioavailability. Furthermore, the NP-based drug delivery systems involve less frequent dosing requirements and in smaller doses which assist in minimizing side effects. In this review, the benefits and limitations of conventional therapies are explored, while providing an in-depth insight on advanced applications of NP-based systems in the treatment of COPD.
